drugset / Trial / NCT00423891

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection

NCT00423891

Phase 1/2 Completed 64 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical study is to determine the appropriate doses of entecavir to use in children and adolescents. Safety, tolerability and efficacy will also be studied

Timeline

Start
2007-06-30
Primary completion
2013-08-31
Completion
2017-09-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Entecavir Small molecule 0.015 mg/kg Oral
Subject Entecavir Small molecule 0.03 mg/kg Oral